Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Immunol Res. 2010 Mar;46(1-3):165-76. doi: 10.1007/s12026-009-8118-5.
Tumor-mediated immune suppression occurs through multiple mechanisms, including dysregulation of dendritic cell differentiation. This block in differentiation results in fewer dendritic cells and an accumulation of immunosuppressive myeloid- derived suppressor cells and is thought to contribute to tumor outgrowth and to act as an impediment to successful anti-cancer immunotherapy. Tumor-mediated myeloid dysregulation is known to be Stat3 dependent; however, the molecular mechanism of this Stat3 signaling remains poorly defined. We have previously shown that PKC betaII is required for dendritic cell differentiation. Here, we describe our finding that tumors mediate both Stat3 activation and PKC betaII down regulation in DC progenitor cells, a process mimicked by the expression of a constitutive active Stat3 mutant. This demonstrates that tumor-mediated myeloid dysregulation may be mediated by Stat3- induced PKC betaII down regulation.
肿瘤介导的免疫抑制通过多种机制发生,包括树突状细胞分化失调。这种分化受阻导致树突状细胞减少,同时抑制性髓系来源的抑制细胞积累,这被认为有助于肿瘤生长,并成为癌症免疫治疗成功的障碍。已知肿瘤介导的髓系失调依赖于 Stat3;然而,这种 Stat3 信号的分子机制仍未明确定义。我们之前已经表明,PKCβII 是树突状细胞分化所必需的。在这里,我们描述了我们的发现,肿瘤在 DC 祖细胞中同时介导 Stat3 的激活和 PKCβII 的下调,这一过程可以通过表达组成性激活的 Stat3 突变体来模拟。这表明肿瘤介导的髓系失调可能是由 Stat3 诱导的 PKCβII 下调介导的。